Bradley A. Keywell Sells 170,720 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 170,720 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total value of $6,052,024.00. Following the sale, the insider now directly owns 15,993,729 shares in the company, valued at approximately $566,977,693.05. This represents a 1.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Tempus AI Stock Up 1.2 %

Shares of NASDAQ TEM opened at $35.15 on Monday. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business’s 50 day moving average is $46.03 and its two-hundred day moving average is $47.27.

Analyst Ratings Changes

Several analysts recently issued reports on TEM shares. Needham & Company LLC reissued a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Piper Sandler reissued a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Bank of America lifted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Wolfe Research started coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Hedge Funds Weigh In On Tempus AI

Large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI during the 3rd quarter worth about $30,000. FNY Investment Advisers LLC purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $67,000. Vestor Capital LLC bought a new position in shares of Tempus AI during the third quarter valued at approximately $153,000. Stifel Financial Corp bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $218,000. Finally, Sandia Investment Management LP bought a new stake in shares of Tempus AI during the 2nd quarter worth approximately $136,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.